GDS Wealth Management Grows Position in DexCom, Inc. (NASDAQ:DXCM)

GDS Wealth Management grew its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 41.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 54,770 shares of the medical device company’s stock after acquiring an additional 16,128 shares during the period. GDS Wealth Management’s holdings in DexCom were worth $6,210,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Migdal Insurance & Financial Holdings Ltd. acquired a new position in shares of DexCom during the 2nd quarter worth $25,000. Sachetta LLC grew its position in shares of DexCom by 255.2% in the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after purchasing an additional 171 shares during the last quarter. DSM Capital Partners LLC acquired a new position in shares of DexCom during the 4th quarter worth approximately $28,000. Crewe Advisors LLC purchased a new stake in DexCom in the 1st quarter valued at approximately $29,000. Finally, Riverview Trust Co purchased a new stake in DexCom in the 1st quarter valued at approximately $32,000. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Price Performance

NASDAQ DXCM opened at $70.09 on Tuesday. The company has a 50-day moving average price of $81.54 and a two-hundred day moving average price of $110.92. DexCom, Inc. has a 52 week low of $62.34 and a 52 week high of $142.00. The stock has a market cap of $27.87 billion, a price-to-earnings ratio of 45.22, a price-to-earnings-growth ratio of 2.12 and a beta of 1.18. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00.

DexCom (NASDAQ:DXCM) last announced its earnings results on Thursday, July 25th. The medical device company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same quarter in the previous year, the business earned $0.34 EPS. The firm’s revenue for the quarter was up 15.3% on a year-over-year basis. Analysts forecast that DexCom, Inc. will post 1.69 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts recently commented on DXCM shares. JPMorgan Chase & Co. cut DexCom from an “overweight” rating to a “neutral” rating and dropped their price objective for the stock from $145.00 to $75.00 in a research report on Friday, July 26th. Barclays dropped their target price on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating for the company in a research report on Monday, July 29th. Wells Fargo & Company reduced their price target on shares of DexCom from $145.00 to $80.00 and set an “overweight” rating on the stock in a research report on Friday, July 26th. UBS Group decreased their price objective on shares of DexCom from $163.00 to $95.00 and set a “buy” rating for the company in a research note on Friday, July 26th. Finally, Canaccord Genuity Group reissued a “buy” rating and issued a $145.00 target price on shares of DexCom in a research note on Tuesday, July 23rd. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $112.25.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In other DexCom news, EVP Sadie Stern sold 426 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Jacob Steven Leach sold 746 shares of DexCom stock in a transaction on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the transaction, the chief operating officer now owns 264,915 shares in the company, valued at $18,318,872.25. The disclosure for this sale can be found here. Insiders have sold a total of 2,483 shares of company stock worth $201,708 over the last ninety days. 0.30% of the stock is currently owned by corporate insiders.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.